Antisense Pharma (Germany) a clinical-stage biopharmaceutical company focused on antisense gene silencing for pancreatic cancer, malignant melanoma and colorectal cancer, closed a $11M Series F financing. Participants include MIG Fonds and Global Asset Fund.
Thanx for your patience as we catch-up.

Circle Cardiovascular Imaging (Canada) a commercial-stage analytical software company focused on cardiac imaging, closed a $3.9M Series B financing. Participants include Business Development Bank of Canada, Foundation Equity and First Yellowhead Equities.
Thanx for your patience as we catch-up.

Monteria Medical (Canada) a development-stage medical device company focused on laser interstitial thermal therapy for the treatment of brain tumors, closed a $8.6M Series C financing. Participants include Business Development Bank of Canada and Southwest Michigan First.
Thanx for your patience as we catch-up.

SpineVision (France) a commercial-stage medical device company focused on spine deformities, lumbar degenerative disc diseases and cervical disorders, closed a $5M Series B financing. Participants include Partner Capital, Sofinnova Ventures, BroadPeak, HealthCap, Innoven and Edbi.
Thanx for your patience as we catch-up.

Horizon Discovery (United Kingdom) a commercial-stage translational genomics company focused on drug discovery and molecular diagnostics, closed a $18.6M Series C financing. Participants include MVM Life Sciences, DFJ Esprit and Roche Venture Fund.
Thanx for your patience as we catch-up.

LifeBond (Israel) a clinical-stage medical device company focused on surgical hemostats, sealants and coagulation, closed a $20M Series C financing. Participants include Giza Venture Capital, Aurum Ventures, Johnson & Johnson Development Corp. and Pitango Venture Capital.
Thanx for your patience as we catch-up.

Enobia Pharma (Canada) a clinical-stage biotech company focused on hypophosphatasia, closed a $40M Series D financing. Participants include OrbiMed, CTI Life Sciences Fund, Desjardins Venture Capital and Lothian Partners.
Thanx for your patience as we catch-up.

Spinifex Pharmaceuticalsx (Australia) a clinical-stage biotechnology company focused on neuropathic pain, closed a $6.4M Series B financing. Participants include GBS Venture Partners, Brandon Capital Partners, Uniseed Management and UniQuest.
Thanx for your patience as we catch-up.

Zymeworks (Canada) a preclinical-stage biopharma focused on protein-based therapeutics for oncology and inflammatory disease, closed a $8.1M Series D financing. Participants include CTI Life Sciences Fund and Advanced Biotechnologies Venture Fund.
Thanx for your patience as we catch-up.

SpineGuard (France) a commercial-stage medical device company focused on increasing accuracy and efficiency of pedicle screw placement in spine surgery, closed a $6.2M Series B bringing the total financing to $15M. Participants include Credit Agricole Private Equity, Innoven Partenaires, A Plus Finance and Delta Partners.
Thanx for ur patience as we catch-up.

MSI Methylation Sciences (Canada) a preclinical-stage pharmaceutical company focused on depression, closed a $18.2M Series A financing. Participants include Inventages, GrowthWorks and BC Advantage Funds.

Miracor Medical Systems (Austria) a development-stage medical device company focused on acute coronary syndrome and heart failure, closed a $10M Series B financing. Participants include Austria Wirtschaftsservice, SHS, Earlybird and Delta Partners.

AM-Pharma (The Netherlands) a clinical-stage pharmaceutical company focused on acute kidney injury and ulcerative colitis, closed a $39.8M Series D financing. Participants include Ysios Capital Partners, Kurma Life Science Partners, Abbott Ventures, Shire Ventures, BB Biotech Ventures, Idinvest Partners, Forbion Capital Partners and Inventages Venture Capital.